Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Am J Obstet Gynecol. 2022 Jan;226(1):97.e1-97.e16. doi: 10.1016/j.ajog.2021.08.029. Epub 2021 Aug 27.
Minimally invasive radical trachelectomy has emerged as an alternative to open radical hysterectomy for patients with early-stage cervical cancer desiring future fertility. Recent data suggest worse oncologic outcomes after minimally invasive radical hysterectomy than after open radical hysterectomy in stage I cervical cancer.
We aimed to compare 4.5-year disease-free survival after open vs minimally invasive radical trachelectomy.
This was a collaborative, international retrospective study (International Radical Trachelectomy Assessment Study) of patients treated during 2005-2017 at 18 centers in 12 countries. Eligible patients had squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma; had a preoperative tumor size of ≤2 cm; and underwent open or minimally invasive (robotic or laparoscopic) radical trachelectomy with nodal assessment (pelvic lymphadenectomy and/or sentinel lymph node biopsy). The exclusion criteria included neoadjuvant chemotherapy or preoperative pelvic radiotherapy, previous lymphadenectomy or pelvic retroperitoneal surgery, pregnancy, stage IA1 disease with lymphovascular space invasion, aborted trachelectomy (conversion to radical hysterectomy), or vaginal approach. Surgical approach, indication, and adjuvant therapy regimen were at the discretion of the treating institution. A total of 715 patients were entered into the study database. However, 69 patients were excluded, leaving 646 in the analysis. Endpoints were the 4.5-year disease-free survival rate (primary), 4.5-year overall survival rate (secondary), and recurrence rate (secondary). Kaplan-Meier methods were used to estimate disease-free survival and overall survival. A post hoc weighted analysis was performed, comparing the recurrence rates between surgical approaches, with open surgery being considered as standard and minimally invasive surgery as experimental.
Of 646 patients, 358 underwent open surgery, and 288 underwent minimally invasive surgery. The median (range) patient age was 32 (20-42) years for open surgery vs 31 (18-45) years for minimally invasive surgery (P=.11). Median (range) pathologic tumor size was 15 (0-31) mm for open surgery and 12 (0.8-40) mm for minimally invasive surgery (P=.33). The rates of pelvic nodal involvement were 5.3% (19 of 358 patients) for open surgery and 4.9% (14 of 288 patients) for minimally invasive surgery (P=.81). Median (range) follow-up time was 5.5 (0.20-16.70) years for open surgery and 3.1 years (0.02-11.10) years for minimally invasive surgery (P<.001). At 4.5 years, 17 of 358 patients (4.7%) with open surgery and 18 of 288 patients (6.2%) with minimally invasive surgery had recurrence (P=.40). The 4.5-year disease-free survival rates were 94.3% (95% confidence interval, 91.6-97.0) for open surgery and 91.5% (95% confidence interval, 87.6-95.6) for minimally invasive surgery (log-rank P=.37). Post hoc propensity score analysis of recurrence risk showed no difference between surgical approaches (P=.42). At 4.5 years, there were 6 disease-related deaths (open surgery, 3; minimally invasive surgery, 3) (log-rank P=.49). The 4.5-year overall survival rates were 99.2% (95% confidence interval, 97.6-99.7) for open surgery and 99.0% (95% confidence interval, 79.0-99.8) for minimally invasive surgery.
The 4.5-year disease-free survival rates did not differ between open radical trachelectomy and minimally invasive radical trachelectomy. However, recurrence rates in each group were low. Ongoing prospective studies of conservative management of early-stage cervical cancer may help guide future management.
对于有生育需求的早期宫颈癌患者,微创根治性宫颈切除术已成为开放根治性子宫切除术的替代方法。最近的数据表明,在 I 期宫颈癌中,微创根治性子宫切除术的肿瘤学结果比开放根治性子宫切除术差。
我们旨在比较开放与微创根治性宫颈切除术的 4.5 年无病生存率。
这是一项合作的、国际回顾性研究(国际根治性宫颈切除术评估研究),纳入了 2005 年至 2017 年在 12 个国家的 18 个中心接受治疗的患者。符合条件的患者患有鳞状细胞癌、腺癌或腺鳞癌;术前肿瘤大小≤2cm;并接受了开放或微创(机器人或腹腔镜)根治性宫颈切除术和淋巴结评估(盆腔淋巴结切除术和/或前哨淋巴结活检)。排除标准包括新辅助化疗或术前盆腔放疗、既往淋巴结切除术或盆腔腹膜后手术、妊娠、IA1 期伴脉管侵犯、流产性宫颈切除术(转为根治性子宫切除术)或阴道入路。手术方法、适应证和辅助治疗方案由治疗机构决定。共有 715 名患者进入研究数据库。然而,有 69 名患者被排除,因此有 646 名患者进入分析。主要终点是 4.5 年无病生存率(一级终点)、4.5 年总生存率(二级终点)和复发率(二级终点)。采用 Kaplan-Meier 方法估计无病生存率和总生存率。进行了事后加权分析,比较了两种手术方法之间的复发率,以开放手术为标准,微创手术为实验。
646 名患者中,358 名患者接受了开放手术,288 名患者接受了微创手术。开放手术患者的中位(范围)年龄为 32(20-42)岁,微创手术患者的中位(范围)年龄为 31(18-45)岁(P=.11)。开放手术患者的中位(范围)病理肿瘤大小为 15(0-31)mm,微创手术患者的中位(范围)病理肿瘤大小为 12(0.8-40)mm(P=.33)。盆腔淋巴结受累率分别为开放手术 5.3%(19/358 例)和微创手术 4.9%(14/288 例)(P=.81)。中位(范围)随访时间分别为开放手术 5.5(0.20-16.70)年和微创手术 3.1 年(0.02-11.10)年(P<.001)。4.5 年时,开放手术 358 例患者中有 17 例(4.7%)和微创手术 288 例患者中有 18 例(6.2%)出现复发(P=.40)。开放手术 4.5 年无病生存率为 94.3%(95%置信区间,91.6-97.0),微创手术为 91.5%(95%置信区间,87.6-95.6)(对数秩检验 P=.37)。术后倾向性评分分析复发风险显示两种手术方法之间无差异(P=.42)。4.5 年时,有 6 例与疾病相关的死亡(开放手术 3 例,微创手术 3 例)(对数秩检验 P=.49)。开放手术 4.5 年总生存率为 99.2%(95%置信区间,97.6-99.7),微创手术为 99.0%(95%置信区间,79.0-99.8)。
开放根治性宫颈切除术与微创根治性宫颈切除术的 4.5 年无病生存率无差异。然而,每组的复发率都很低。正在进行的早期宫颈癌保守治疗的前瞻性研究可能有助于指导未来的治疗。